International CRDS Registry
ConditionCalcium Release Deficiency Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPopulation Health Research Institute
About this trial
Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
The registry will enrol 3 separate cohorts. The primary cohort consists of CRDS cases. A CRDS case is defined as an individual that possesses a rare RYR2 variant proven to be loss-of-function on in vitro analysis. A second cohort consists of individuals that possess a rare RYR2 truncating variant or large copy number variant. The third cohort involves individuals suspected of having CRDS, however in vitro analysis revealed that their rare RYR2 variant did not impact function.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 3 trial groupsGroup A: CRDS
Group B: Carrier of an RYR2 truncating variant or large copy number variant
Group C: Carrier of a non-functional RYR2 rare variant
Trial outcomes
Primary outcomes
1
Malignant Ventricular Arrhythmia
Composite of malignant syncope, ICD shock, cardiac arrest, and sudden cardiac death
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Population Health Research Institute
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Source ClinicalTrials.gov